<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en">
<head><meta http-equiv="Content-Type" content="text/html; charset=">
<title>Handoff Notes and Reminders
</title>
</head>

<body >


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><img height="51" width="198" src="Cardio%20ExCC%20Weitz%20239054-50%20v300.jpg" 	alt="Medscape logo VBA" border="0" ></p>
</td>
<td><p><strong>Production Ticket</strong></p>
</td>
</tr>

</table>
<p></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Who?</strong></p>
</td>
<td><p><strong>When?</strong></p>
</td>
<td><p><strong>What?</strong></p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Y Yamaguchi</p>
</td>
<td><p>5/4/18</p>
</td>
<td><p>Initiated ticket</p>
</td>
</tr>

<tr valign="top">
<td><p>K Paul-Pletzer</p>
</td>
<td><p>8/26/18</p>
</td>
<td><p>Added content</p>
</td>
</tr>

<tr valign="top">
<td><p>K Paul-Pletzer</p>
</td>
<td><p>8/27/18</p>
</td>
<td><p>Added post-test questions</p>
</td>
</tr>

<tr valign="top">
<td><p>Y Yamaguchi</p>
</td>
<td><p>8/28/18</p>
</td>
<td><p>Disclosures</p>
</td>
</tr>

<tr valign="top">
<td><p>N Dunford</p>
</td>
<td><p>9/4/18</p>
</td>
<td><p>Content accuracy review</p>
</td>
</tr>

<tr valign="top">
<td><p>K Paul-Pletzer</p>
</td>
<td><p>9/4/18</p>
</td>
<td><p>Prepared for copyedit</p>
</td>
</tr>

<tr valign="top">
<td><p>D Frassetto</p>
</td>
<td><p>9/7/18</p>
</td>
<td><p>Copyedit</p>
</td>
</tr>

<tr valign="top">
<td><p>K Paul-Pletzer</p>
</td>
<td><p>9/07/18</p>
</td>
<td><p>Reviewed copyedits; prepared for CME review</p>
</td>
</tr>

<tr valign="top">
<td><p>E Nyarko</p>
</td>
<td><p>9/12/18</p>
</td>
<td><p>CME, ABIM MOC Review</p>
</td>
</tr>

<tr valign="top">
<td><p>K Paul-Pletzer</p>
</td>
<td><p>9/13/18</p>
</td>
<td><p>Addressed CME comment; prepared for production</p>
</td>
</tr>

</table>
<p>Click <strong>+</strong> to add another table row</p>

<p>&#953; = additional instructions available when you hover cursor over; <strong>Bold text</strong> = questions to be answered</p>
<h1>
<a name="HandoffNotes"></a><a name="Heading41"></a><strong>Handoff Notes and Reminders</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>To Scientific Directors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Copyeditors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Production/Studio &#953;</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To CME Department</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading50"></a><strong>General Information</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Activity SF#(s):</strong></p>
</td>
<td><p>239054-50</p>
</td>
<td><p><strong>Related SF#s &#953;:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Supporter(s):</strong></p>
</td>
<td><p>Bayer AG</p>
</td>
<td><p><strong>Partner (s):</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Product type:</strong></p>
</td>
<td><p>Curbside Consult</p>
</td>
<td><p><strong>If live event, enter date:</strong></p>
</td>
<td><p>(Click to enter date...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Peer review required?</strong></p>
</td>
<td><p>Yes</p>
</td>
<td><p><strong>IME program?</strong></p>
</td>
<td><p>&#9746; No   &#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Outcomes Study included? &#953;</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; <strong>measurement focus:</strong> </p>
</td>
<td><p>&#9744; Competence     &#9744; Performance    &#9744;Patient Outcomes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Geotargets &#953;</strong></p>
</td>
<td><p><strong>1:</strong> Global</p>
</td>
<td><p><strong>2:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>3:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>4:</strong> (Choose a geotarget...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Select one supporter attribution:</strong></p>

<p>&#9746; One Supporter: supported by Bayer AG</p>

<p>&#9744; Multi-Support: supported by independent educational grants from (Insert names of supporters...)</p>

<p>&#9744; Medscape-supported activity: developed and funded by Medscape</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Type of badge:</strong></p>
</td>
<td><p>&#9746; Text only</p>
</td>
<td><p>&#9744; Supporter logo</p>
</td>
<td><p>&#9744; Text and supporter logo</p>
</td>
</tr>

<tr valign="top">
<td><p>Paste badge(s) here: <img height="60" width="267" src="Cardio%20ExCC%20Weitz%20239054-50%20v301.jpg" 	alt="Cardio%20ExCC%20Weitz%20239054-50%20v301.jpg" border="0" ></p>
</td>
</tr>

</table>
<h1>
<a name="Heading85"></a><strong>Course/CME Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Title: &#953;</strong></p>
</td>
<td><p>VTE in Cancer: What Do the Latest Data Suggest?</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Teaser: &#953;</strong></p>
</td>
<td><p>Drs Weitz and Khorana discuss the evolving treatment paradigm of cancer-associated venous thromboembolism.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Faculty/Author(s) Byline(s): &#953;</strong></p>
</td>
<td><p>Jeffrey I. Weitz, MD, FRCP(C); Alok A. Khorana, MD</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Indicate thumbnail URL &#953;:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Target Audience:</strong></p>
</td>
<td><p>This activity is intended for cardiologists, hematology and oncology specialists, and primary care physicians.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Goal Statement: </strong></p>
</td>
<td><p>The goal of this activity is to inform physicians of the latest data on the treatment and prevention of cancer-associated venous thromboembolism (VTE) and their implications for clinical practice. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Educational Design &#953;</strong></p>
</td>
<td><p>&#9746; Competence &#953;</p>
</td>
<td><p>&#9744; Performance &#953;</p>
</td>
<td><p>&#9744; Patient Outcomes &#953;</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Core Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Patient care and procedural skills</p>
</td>
<td><p>&#9746; Medical knowledge</p>
</td>
<td><p>&#9744; Practice-based learning and improvement </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interpersonal &amp; communication skills</p>
</td>
<td><p>&#9744; Professionalism</p>
</td>
<td><p>&#9744; Systems-based practice</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>IPCE Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Interprofessional Education (IPCE)</p>
</td>
<td><p>&#9744; Roles and Responsibilities</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interprofessional Communication</p>
</td>
<td><p>&#9744; Teamwork &#953;</p>
</td>
<td><p>&#9744; Values and Ethics</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Length &#953;:</strong></p>
</td>
<td><p>27 min video runtime</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Credits Available &#953;:</strong></p>

<p>&#9746;<strong> Medscape Joint Accreditation Statement </strong></p>

<p>Direct Provider:</p>

<p>In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>

<p><img height="79" width="124" src="Cardio%20ExCC%20Weitz%20239054-50%20v302.jpg" 	alt="Cardio%20ExCC%20Weitz%20239054-50%20v302.jpg" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p>&#9746; <strong>ACCME:</strong> 0.50 AMA PRA Category 1&#8482; Credit:</p>

<p>For Physicians</p>

<p>Medscape, LLC designates this enduring material for a maximum of 0.50 <strong><em>AMA PRA Category 1 Credit(s)&#8482;</em></strong>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>ANCC:</strong> (Select credit hours...) contact hours (Select credit hours...) contact hours are in the area of pharmacology)</p>

<p>(Select...)</p>

<p>&#9746; <strong>ABIM MOC:  PARS Activity Identifier </strong>201130046</p>
</td>
</tr>

<tr valign="top">
<td><p>Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>ACPE:</strong> Knowledge-based (Select credit hours...) CEUs); Application-based (Select credit hours...) CEUs)</p>

<p>(Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>CPD:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>OUS Options:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>IME:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>Other:</strong> (Click here to enter...)</p>
</td>
</tr>

</table>
<h1>


<a name="Heading141"></a><a name="Heading142"></a><strong>Partner Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Partner Statement:</strong></p>

<p><strong>(edit standard statement if needed)</strong></p>
</td>
<td><p>Developed through a partnership between Medscape and enter partner. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner source marker required?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; enter partner abbreviation here: (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner logo required?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; paste logo here:</p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Required passing score:</strong></p>
</td>
<td>&nbsp;</td>
<td><p><strong>Evaluation required?</strong></p>
</td>
<td><p>&#9746; Yes     &#9744; No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Copyright Statement:</strong></p>
</td>
<td><p>&#9746; &#169;2018 Medscape, LLC</p>
</td>
<td><p>&#9744; &#169;2018 WebMD Global, LLC</p>
</td>
<td><p>&#9744; &#169;2018 (Add Partner&#8217;s copyright statement...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading161"></a><strong>Collection Page Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there a collection page?</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; <strong>what type?</strong> Clinical Advances; <strong>provide name and URL:</strong> Clinical Advances in Anticoagulation Management and Vascular Protection    https://www.medscape.org/sites/advances/anticoagulation-thrombosis</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>	If 'Clinical Advances,' which bucket does the content go in?</strong> VTE</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Add to other publications or pages?</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: medscape.org/oncology</p>
</td>
</tr>

</table>
<h1>
<a name="Heading171"></a><strong>Product-Specific Information and Add-ons</strong></h1>
<p><em>See Spec Sheet for product-specific details for all products prior to completing this section, especially for a </em><strong><em>multicomponent activity</em> &#953;</strong><em>, </em><strong><em>Slideshow</em> &#953;</strong><em>, and </em><strong><em>Test and Teach</em> &#953;</strong><em>. <strong>A&#160;building block is provided to assist in adding custom components for Directed Learning and </strong></em><strong><em>multicomponent activities</em> &#953;<em> below.</em></strong><em> </em></p>

<p>(Select building block)</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there an Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a second Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Medscape Discuss</p>
</td>
<td><p>&#9744; Medscape Discuss Lite</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there an associated HCP Perspective?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is this program associated with a Patient Education Program or Destination Page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Provide server path for Prescription to Learn PDF:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>


<a name="Heading190"></a><a name="Heading191"></a><strong>Learning Objectives and KMI Map</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Upon completion of this activity, participants will:</strong></p>
</td>
<td><p><strong>Question type assessing this objective</strong></p>
</td>
<td><p>Question #</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Have increased knowledge regarding the</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>Current and emerging approaches to primary prevention of VTE in patients with cancer</p>

<p>Guideline recommendations on treatment of VTE in patients with cancer</p>

<p>Latest non-vitamin K antagonist oral anticoagulant (NOAC) data on treatment of VTE in patients with cancer</p>
</td>
<td><p>Posttest</p>
</td>
<td><p>2</p>

<p>1</p>

<p>1</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>(Select response...)</p>
</td>
<td>&nbsp;</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<p>Click <strong>+</strong> to add another table row</p>
<h1>
<a name="Heading214"></a><strong>Questions (Evaluations, Assessments, and Posttests)</strong></h1>
<p></p>

<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 1:</strong> In which of the following patients with active cancer and venous thromboembolism (VTE) could a non-vitamin K antagonist oral anticoagulant (NOAC) be considered for the treatment of VTE?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	A patient with luminal gastrointestinal (GI) cancer</p>

<p>&#8226;	A patient with breast cancer</p>

<p>&#8226;	A patient with bladder cancer</p>

<p>&#8226;	A patient with prostate cancer and esophagitis</p>

<p>Answer explanation: The International Society on Thrombosis and Haemostasis (ISTH) has provided guidance on the use of NOACs for the treatment of cancer-associated VTE. This guidance is based on data from Hokusai VTE-Cancer (edoxaban) and SELECT-D (rivaroxaban) trials. Both trials showed a greater reduction of VTE recurrence with the NOAC vs dalteparin. Major bleeding was, however, greater with the NOAC but was mostly confined to patients with GI cancer. Accordingly, the ISTH suggests that these 2 NOACs may be considered for VTE treatment in patients with cancer who are at low risk of bleeding. In cancers with a high risk of bleeding (luminal GI, genitourinary [GU] tract, and bladder) or patients with cancer who have active GI mucosal abnormalities (duodenal ulcers, gastritis, esophagitis, or colitis), ISTH suggests the use of low-molecular-weight heparin (LMWH) for VTE treatment. Patients with breast cancer had a low incidence of major bleeding in the two NOAC trials. </p>



<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 2:</strong> What is the current recommendation for the primary prevention of VTE in patients with cancer?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Routine thromboprophylaxis should be considered in all patients with cancer as they are at increased risk of VTE</p>

<p>&#8226;	Thromboprophylaxis is mandatory in patients with primary brain tumors as they are at high risk of VTE</p>

<p>&#8226;	Thromboprophylaxis should be considered in high-risk outpatients receiving chemotherapy</p>

<p>&#8226;	Routine thromboprophylaxis should be considered in all outpatients with cancer who have a low risk of bleeding</p>

<p>Answer explanation: Compared with the general population without cancer, patients with cancer are at increased risk of VTE, but the risk varies considerably across cancer types. Thus, routine thromboprophylaxis is not recommended in unselected, low-risk outpatients with cancer or in patients with high risk of bleeding, such as with primary brain tumors. Conversely, thromboprophylaxis with LMWH should be considered in high-risk outpatients with cancer (Khorana score &#8805;3 or advanced pancreatic cancer) who are receiving chemotherapy. This recommendation is based on clinical trials that showed a benefit for thromboprophylaxis in the subgroup of patients with high risk of VTE. Clinical trials with NOACs for the prevention of cancer-associated VTE are ongoing. The results of these trials are expected to clarify the role of NAOCs for thromboprophylaxis in patients with cancer. </p>
<h1>
<a name="Heading236"></a><strong>Content</strong></h1>
<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; 00:00 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; VTE in Cancer: What Do the Latest Data Suggest?</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Cancer and VTE Risk; 00:52 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Risk of Cancer-Associated VTE</strong><sup>[1-4]</sup> </p>

<p>&#8226;	Risk of venous thromboembolism (VTE) is elevated in cancer</p>

<p>&#8226;	In general, patients with cancer have a 1:5 chance of developing VTE</p>

<p>&#8226;	VTE risk is variable and dependent on a number of factors, including</p>

<p><tt>o	</tt>Cancer type (site of tumor)</p>

<p><tt>o	</tt>Cancer stage</p>

<p><tt>o	</tt>Time since diagnosis of cancer</p>

<p><tt>o	</tt>Cancer treatment</p>

<p>&lt;&lt;insert slide 3: 01:12 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Cancer Site</strong><sup>[4]</sup> </p>

<p>&#8226;	The predominant risk factor is the location of the primary tumor</p>

<p>&#8226;	Overall, gastrointestinal (GI), pancreas, brain, lung, and ovarian cancer induce the highest risks</p>

<p>&#8226;	Relatively lower risks are seen in patients with breast or prostate cancer</p>

<p>&lt;&lt;insert slide 4: 02:27 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Cancer Treatment Modality</strong><sup>[5]</sup> </p>

<p>&lt;&lt;insert slide 5: 04:25 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Patient-Related Factors</strong><sup>[5]</sup> </p>

<p>&#8226;	Ethnicity</p>

<p><tt>o	</tt>Risk greater with African American vs Caucasian vs Asian population</p>

<p><tt>o	</tt>Attributed risk, however, is minor</p>

<p>&#8226;	Compression of major vessels by tumors</p>

<p>&lt;&lt;insert slide 6; Chapter Title: LMWH for VTE Treatment; 05:18 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Guideline Recommendations: Cancer-Associated VTE Treatment</strong><sup>[6-8]</sup> </p>

<p>&#8226;	Most guidelines recommend monotherapy with low-molecular-weight heparin (LMWH) for at least 6 months</p>

<p>&#8226;	Latest data from VTE treatment trials with non-vitamin K antagonist oral anticoagulants (NOACs) are challenging the current treatment paradigm</p>

<p>&lt;&lt;insert slide 7: 06:54 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Challenges With LMWH</strong></p>

<p>&#8226;	LMWHs are injectable agents</p>

<p><tt>o	</tt>Injectable agents are treated differently in prescription plans and copayment can be high</p>

<p><tt>o	</tt>Daily self-injection adds to the burden of treatment</p>

<p>&lt;&lt;insert slide 8: 07:32 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Persistence With Anticoagulation for Cancer-Associated VTE</strong><sup>[9]</sup> </p>

<p>&#8226;	Real-world analysis: LMWH was associated with significantly lower persistence and shorter duration of treatment</p>

<p>&lt;&lt;insert slide 9: 08:33 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; VTE and Major Bleeding Risk in Patients Receiving Chemotherapy: A Real-World Analysis</strong><sup>[10]</sup> </p>

<p>&#8226;	Patients with cancer are at high risk of both VTE and major bleeding</p>

<p>&#8226;	VTE and major bleeding can be fatal</p>

<p>&#8226;	Major bleeding can be difficult to treat; especially GI mucosal bleeding</p>

<p>&#8226;	Minor (eg, nuisance) bleeding is also common</p>

<p>&lt;&lt;insert slide 10; Chapter Title: NOACS for VTE Treatment; 09:24 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Treatment of Cancer-Associated VTE: Clinical Trials of NOACs</strong><sup>[11-13]</sup> </p>

<p>&lt;&lt;insert slide 11: 10:36 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Design</strong><sup>[14]</sup> </p>

<p>&#8226;	Study population with active cancer and symptomatic/incidental deep vein thrombosis (DVT) or proximal pulmonary embolism (PE)</p>

<p><tt>o	</tt>DVT of proximal lower extremity (popliteal, femoral, or iliac vein thrombosis)</p>

<p><tt>o	</tt>PE involving segmental or more proximal pulmonary arteries</p>

<p>&#8226;	All patients were treated for at least 6 months</p>

<p>&#8226;	Physicians were encouraged to continue treatment for 12 months</p>

<p>&lt;&lt;insert slide 12: 11:45 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Primary Outcome</strong><sup>[11]</sup> </p>

<p>&#8226;	Edoxaban was noninferior to dalteparin</p>

<p>&lt;&lt;insert slide 13: 12:05 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Primary Outcome Components</strong><sup>[11]</sup> </p>

<p>&#8226;	Rate of recurrent VTE was significantly lower with edoxaban vs dalteparin</p>

<p>&#8226;	Rate of major bleeding was significantly higher with edoxaban vs dalteparin</p>

<p>&#8226;	Most major bleeding occurred in patients with GI cancers</p>

<p>&lt;&lt;insert slide 14: 13:11 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Design</strong><sup>[15]</sup> </p>

<p>&#8226;	Study population similar to Hokusai VTE-Cancer</p>

<p>&lt;&lt;insert slide 15: 13:37 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Primary Endpoint &#8211; Recurrent VTE at 6 Months</strong><sup>[12]</sup> </p>

<p>&#8226;	Rivaroxaban was associated with relatively low VTE recurrence compared with dalteparin</p>

<p>&lt;&lt;insert slide 16: 13:48 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Major and CRNM Bleeding at 6 Months</strong><sup>[12]</sup> </p>

<p>&#8226;	Rivaroxaban was associated with relatively higher clinically relevant nonmajor (CRNM) bleeding compared with dalteparin</p>

<p>&#8226;	Most of the major bleeding occurred in patients with GI cancers</p>

<p>&lt;&lt;insert slide 17: 15:01 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Major Bleeding by Tumor Type</strong><sup>[12]</sup> </p>

<p>&#8226;	Among GI cancers, most major bleeding was confined to upper GI cancers</p>

<p>&lt;&lt;insert slide 18: 15:28 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Major Bleeding by Tumor Type</strong><sup>[16]</sup> </p>

<p>&#8226;	Excess major bleeding with edoxaban was confined to patients with GI cancer</p>

<p>&lt;&lt;insert slide 19; Chapter Title: Guidance on Use of NOACs; 16:38 &gt;&gt;</p>

<p><strong>&lt;&lt;Level 2&gt;&gt; NOACs for Treatment of Cancer Associated VTE: Guidance From ISTH</strong><sup>[17]</sup> </p>

<p>&#8226;	An estimated 60% to 70% of overall cancer population may be eligible for treatment with NOACs</p>

<p>&#8226;	In patients with high risk of bleeding, reassess therapy options when bleeding risk changes over time</p>

<p>&#8226;	Patients with severe thrombocytopenia are candidates for LMWH</p>

<p><tt>o	</tt>LMWH can be dose-adjusted based on the platelet count</p>

<p><tt>o	</tt>Fine tuning of dose is not currently possible with NOACs</p>

<p>&lt;&lt;insert slide 20: 18:55 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Anticoagulation in Cancer Patients With Thrombocytopenia: Guidance From ISTH</strong><sup>[18]</sup> </p>

<p>&#8226;	Option to start with one therapy and switch to another when patient condition improves</p>

<p>&#8226;	For example, in patients with GI cancer</p>

<p><tt>o	</tt>Could start therapy with LMWH</p>

<p><tt>o	</tt>If bleeding risk improves, switch to a NOAC</p>

<p><tt>o	</tt>If platelet count declines after switching to NOAC, bridge to LMWH until platelet count improves to safely resume NOAC</p>

<p>&lt;&lt;insert slide 21; Chapter Title: VTE Prevention; 22:33 &gt;&gt;</p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Guidance for Prevention of Cancer-Associated VTE</strong><sup>[19]</sup> </p>

<p>&#8226;	Clinical trials on thromboprophylaxis found benefit in patients with high risk score (Khorana score &#8805;3)</p>

<p>&#8226;	Although thromboprophylaxis is recommended in patients with cancer who are at high risk of VTE, it is not usually followed</p>

<p>&lt;&lt;insert slide 22: 23:30 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; CASSINI: Design</strong><sup>[20]</sup> </p>

<p>&lt;&lt;insert slide 23: 24:07 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; AVERT: Design</strong><sup>[21]</sup> </p>

<p>&lt;&lt;insert slide 24; Chapter Title: Summary; 24:50 &gt;&gt;</p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Summary</strong></p>

<p>&lt;&lt;insert slide 25: 25:36 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Summary (cont)</strong></p>

<p>&lt;&lt;insert slide 26: 27:04 &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Thank you</strong></p>

<p>&lt;&lt;end slides&gt;&gt;</p>

<p><em>This content has been condensed for improved clarity.</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading368"></a><strong>Abbreviations</strong></h1>
<p>aRR = adjusted relative risk</p>

<p>cat. = category</p>

<p>CAT = cancer-associated thrombosis</p>

<p>CI = confidence interval</p>

<p>CrCl = creatinine clearance</p>

<p>CRNM = clinically relevant nonmajor</p>

<p>CVC = central venous catheters</p>

<p>DVT = deep vein thrombosis</p>

<p>ESA = erythropoiesis-stimulating agent</p>

<p>GI = gastrointestinal</p>

<p>GU = genitourinary</p>

<p>HR = hazard ratio</p>

<p>IMiD = immunomodulatory drug</p>

<p>IR = incidence rate</p>

<p>ISTH = International Society on Thrombosis and Haemostasis</p>

<p>LMWH = low-molecular-weight heparin</p>

<p>NA = not applicable</p>

<p>NOAC = non-vitamin K antagonist oral anticoagulant </p>

<p>OR = odds ratio</p>

<p>PE = pulmonary embolism</p>

<p>RR = relative risk</p>

<p>RVT = residual vein thrombosis </p>

<p>UFH = unfractionated heparin</p>

<p>VTE = venous thromboembolism</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading394"></a><strong>Additional Resources</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><em>Add additional resources below. NOTE: If a <strong>custom downloadable slide kit or custom downloadable PDF</strong> was sold above the </em><strong><em>standard decks</em> &#953;</strong><em> and resources that come with certain activities, it should be noted in the </em><a href="Cardio%20ExCC%20Weitz%20239054-50%20v3.html#HandoffNotes">HANDOFF NOTES AND REMINDERS</a><em> section above (include the custom label for document as well). <strong>Do not indicate here.</strong></em></p>
</td>
</tr>

</table>
<h1>
<a name="Heading397"></a><strong>Related Links</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><em>List 3 to 5 related links to </em><strong><em>content</em> &#953;</strong><em> on medscape.org and the titles of the activities to be added to this activity.</em></p>

<p>1. <a href="https://www.medscape.org/sites/advances/anticoagulation-thrombosis">https://www.medscape.org/sites/advances/anticoagulation-thrombosis</a> (CLINICAL ADVANCES IN Anticoagulation Management and Vascular Protection)</p>

<p>2. <a href="https://www.medscape.org/viewarticle/890049">https://www.medscape.org/viewarticle/890049</a> (Thrombosis, Cancer, and NOACs: A New Triad in the Making)</p>

<p>3. <a href="https://www.medscape.org/viewarticle/885454">https://www.medscape.org/viewarticle/885454</a> (Complex Cases in Thromboembolic Disease) </p>
</td>
</tr>

</table>
<h1>
<a name="Heading402"></a><strong>Disclosures</strong></h1>
<h2>
<a name="Heading403"></a><strong>Faculty Information and Disclosure Statements</strong></h2>
<p><strong><em>Reminder: Complete the COI statements in the Work Front Custom Form prior to sending this document to CME Review</em></strong></p>

<p><strong><em>List in order as to appear on the site; include "host," "moderator," "panelists," or other type of faculty designation when applicable</em></strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td>
    
<p><strong>Moderator</strong></p>

<p><strong>Jeffrey I. Weitz, MD, FRCP(C)</strong></p>

<p>Professor of Medicine</p>

<p>McMaster University </p>

<p>Hamilton, Ontario, Canada</p>

<p>Disclosure: Jeffrey I. Weitz, MD, FRCP(C), has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Bayer AG; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Portola Pharmaceuticals, Inc.</p>

<p>Dr Weitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Dr Weitz does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p><strong>Panelist</strong></p>

<p><strong>Alok A. Khorana, MD</strong></p>

<p>Professor of Medicine</p>

<p>Cleveland Clinic Lerner College of Medicine</p>

<p>Cleveland, Ohio, United States</p>

<p>Disclosure: Alok A. Khorana, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: AngioDynamics; Bayer AG; Halozyme Therapeutics; Janssen Pharmaceuticals; Pfizer Inc.</p>

<p>&#9746; Received grants for clinical research from: Amgen Inc.</p>

<p>Dr Khorana does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Dr Khorana does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p><strong>Steering Committee</strong></p>

<p><strong>Faculty Information and Disclosure Statements</strong></p>

<p><strong>Anticoagulation Management Steering Committee </strong></p>

<p><strong>Chair: </strong></p>

<p><strong>Keith A.A. Fox, MBChB, FRCP, FMedSci</strong></p>

<p>Professor of Cardiology, University of Edinburgh, Edinburgh, United Kingdom</p>

<p>Disclosure: Keith A.A. Fox, MBChB, FRCP, FMedSci, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc; Sanofi </p>

<p>Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer AG; GlaxoSmithKline; Janssen Pharmaceuticals, Inc. </p>

<p>Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi</p>

<p><strong>Members:</strong></p>

<p><strong>Craig I. Coleman, PharmD</strong></p>

<p>Professor, University of Connecticut, Storrs, Connecticut </p>

<p>Disclosure: Craig I. Coleman, PharmD, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc. </p>

<p>Served as a speaker or a member of a speakers bureau for: Bayer AG; Janssen Pharmaceuticals, Inc.</p>

<p>Received grants for clinical research from: Bayer AG; Janssen Pharmaceuticals, Inc.; Zoll Medical Corporation</p>

<p><strong>Gilles Montalescot, MD, PhD</strong></p>

<p>Professor of Cardiology, Institut de Cardiologie, H&ocirc;pital la Piti&eacute;-Salp&ecirc;tri&egrave;re, Paris, France</p>

<p>Disclosure: Gilles Montalescot, MD, PhD, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Lilly; Medtronic, Inc.; Menarini; Merck Sharp &amp; Dohme GmbH; Pfizer Inc.; sanofi-aventis</p>

<p>Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer AG; Bristol-Myers Squibb Company; Medtronic, Inc.; Pfizer Inc.; sanofi-aventis</p>

<p><strong>Christian T. Ruff, MD, MPH</strong></p>

<p>Assistant Professor of Medicine, TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts</p>

<p>Disclosure: Christian T. Ruff, MD, MPH, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Portola Pharmaceuticals</p>

<p>Received grants for clinical research from: Daiichi Sankyo, Inc.</p>

<p><strong>Mike Sharma, MD, MSc, FRCPC</strong></p>

<p>Associate Professor, Division of Neurology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada </p>

<p>Disclosure: Mike Sharma, MD, MSc, FRCPC, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: AZTherapies, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; </p>

<p>Served as a speaker or a member of a speakers bureau for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company</p>

<p><strong>Peter Verhamme, MD, PhD</strong></p>

<p>Professor, University of Leuven, Leuven, Belgium </p>

<p>Disclosure: Peter Verhamme, MD, PhD, has disclosed the following relevant financial relationships: </p>

<p>Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; LEO Pharma; Medtronic, Inc.; Pfizer Inc; Portola Pharmaceuticals</p>

<p>Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; LEO Pharma; Pfizer Inc</p>

<p>Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; LEO Pharma; Sanofi </p>

<p><strong>Atul Verma, MD, FRCPC, FHRS</strong></p>

<p>Associate Professor, University of Toronto; Director, Heart Rhythm Program, Southlake Regional Health Center, University of Toronto, Newmarket, Ontario, Canada</p>

<p>Disclosure: Atul Verma, MD, FRCPC, FHRS, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: Bayer HealthCare; Biosense Webster, Inc.; Medtronic, Inc.</p>

<p>Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; SERVIER</p>

<p>Received grants for clinical research from: Bayer HealthCare; Biosense Webster, Inc.; Medtronic, Inc. </p>

<p><strong>Vascular Protection Steering Committee </strong></p>

<p><strong>Chair: </strong></p>

<p><strong>Keith A.A. Fox, MBChB, FRCP, FMedSci</strong></p>

<p>Professor of Cardiology, University of Edinburgh, Edinburgh, United Kingdom</p>

<p>Disclosure: As listed above.</p>

<p><strong>Members:</strong></p>

<p><strong>Victor Aboyans, MD, PhD</strong></p>

<p>Professor; Head of Department of Cardiology, Dupuytren University Hospital, Limoges, France</p>

<p>Disclosure: Victor Aboyans, MD, PhD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Bayer AG</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.</p>

<p><strong>Deepak L. Bhatt, MD, MPH</strong></p>

<p>Professor of Medicine, Harvard Medical School; Executive Director, Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart &amp; Vascular Center, Boston, Massachusetts</p>

<p>Disclosure: Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Received grants for clinical research from: Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Chiesi Pharmaceuticals, Inc.; Eisai Inc.; Ethicon, Inc.; Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Lilly; Medtronic, Inc.; Pfizer Inc.; Roche; sanofi-aventis; The Medicines Company; </p>

<p><strong>Christoph Bode, MD</strong></p>

<p>Professor and Chairman, Cardiology and Angiology, Heart Center Freiburg University, Freiburg, Germany</p>

<p>Disclosure: Christoph Bode, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Merck Sharp &amp; Dohme GmbH</p>

<p><strong>Martin R. Cowie, MD, MSc, FRCP, FRCP (Ed), FESC</strong></p>

<p>Professor of Cardiology, Imperial College London, Royal Brompton Hospital, London, United Kingdom</p>

<p>Disclosure: Martin R. Cowie, MD, MSc, FRCP, FRCP (Ed), FESC, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for:  Abbott Laboratories; Bayer AG; Boston Scientific; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; SERVIER</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Bayer AG; Boston Scientific; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Roche; SERVIER</p>

<p>&#9746; Received grants for clinical research from: Bayer AG; Boston Scientific; Medtronic, Inc.; ResMed; Roche</p>

<p><strong>John W. Eikelboom, MBBS, MSc</strong></p>

<p>Associate Professor, Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada</p>

<p>Disclosure: John W. Eikelboom, MBBS, MSc, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc. </p>

<p>Received grants for clinical research from: Bayer AG; Daiichi Sankyo, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; sanofi-aventis</p>

<p><strong>Manesh R. Patel, MD</strong></p>

<p>Professor of Medicine, Duke University Medical Center, Durham, North Carolina, United States</p>

<p>Disclosure: Manesh R. Patel, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for:  Bayer AG; Genzyme Corporation; Janssen Pharmaceuticals, Inc.</p>

<p>&#9746; Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Johnson&#160;&amp;&#160;Johnson Pharmaceutical Research &amp; Development, L.L.C.; MAQUET, Inc.; Tryton Medical</p>

<p><strong>Notes to AME:</strong></p>

<p>For each editor, include the following:</p>

<p>a. Full name; b. Degree; c. Academic Title; d. Affiliation; e. City, State; f. Financial Disclosure Statement; g. Role in the development of the program</p>

<p>Faculty should be listed in this format:</p>

<p>John A. Smith, MD, PhD Professor of Medicine, Harvard Medical School; Chief, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts</p>

<p><strong>Default statement for role of faculty (modify if necessary)</strong></p>

<p>Our Experts: This group of medical professionals have provided guidance on the creation of these programs and resources.</p>

<p>Special Instructions for <strong>EBAC</strong> programs or faculty from <strong>Johns Hopkins University or Emory University/Healthcare</strong>: Special disclosure language or disclaimer statements must be used (EBAC: place BEFORE authors; JHU and Emory place statement AFTER faculty affiliation and BEFORE disclosure information):</p>

<p>(Select disclosure statement...)</p>
</td>
<td><p><strong>Notes to PE:</strong></p>

<p>For each editor, include the following:</p>

<p>a. Full name; b. Degree; c. Academic Title; d. Affiliation; e. City, State/Province, Country (country is only needed for OUS programs); f. Financial Disclosure Statement; g. Role in the development of the program</p>

<p>Faculty should be listed in this format (all info should be linear, not on separate lines):</p>

<p>John A. Smith, MD, PhD Professor of Medicine, Harvard Medical School; Chief, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts</p>

<p><strong>If there a Steering Committee associated with this activity, add information and disclosures for any Steering Committee members not already a part of the activity in the same format. Off-label and Investigational Statements are not used for Steering Committee.</strong> </p>
</td>
</tr>

</table>
<h2>
<a name="Heading559"></a><strong>SD/Editor/Writer Information and Disclosure Statements</strong></h2>
<p><strong><em>List in order as to appear on the site.</em></strong><em> Click </em><strong>+</strong><em> to add more</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Caroline M. Padbury, BPharm</p>

<p>Lead Scientific Director, Medscape, LLC</p>

<p>Disclosure: Caroline M. Padbury, BPharm, has disclosed no relevant financial relationships.</p>

<p>Kalanethee Paul-Pletzer, PhD</p>

<p>Scientific Director, Medscape, LLC</p>

<p>Disclosure: Kalanethee Paul-Pletzer, PhD, has disclosed no relevant financial relationships.</p>
</td>
<td><p>For each editor, include the following:</p>

<p>a) Full name; b) Degree; c) Academic Title; d) Affiliation;  e) City, State; f) Financial Disclosure Statement; g) Role in the development of the program</p>

<p>Medscape SD/ED affiliations should be listed in this format:</p>

<p>Jane Doe, PhD  Scientific Director, Medscape, LLC</p>
</td>
</tr>

</table>
<h2>
<a name="Heading573"></a><strong>Additional Planners/Reviewers Information and Disclosure Statements</strong></h2>
<p><strong><em>Select the appropriate CME reviewer involved in the project using the building block below.</em></strong><em> Click </em><strong>+</strong><em> to add more reviewers</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p></p>

<p><strong>CME Reviewer &#953;</strong></p>

<p>Esther Nyarko, PharmD Associate Clinical CME Director, Medscape, LLC</p>

<p>Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.</p>

<p><strong>Nurse Planner</strong></p>

<p>Amy Bernard, MS, BSN, RN-BC Lead Nurse Planner(Select &#8220;Medcape, LLC&#8221; for non-OUS programs...)</p>

<p>Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.</p>

<p><strong>Peer Reviewer</strong></p>

<p>This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: </p>

<p>Served as an advisor or consultant for: Abbott Laboratories; Medtronic, Inc.</p>
</td>
<td><p>Indicate which reviewers were involved with the project; Add others as necessary (such as peer reviewers; Partner Planners/ Reviewers)</p>

<p><strong>Include Peer Reviewer <em>information only if required by partner</em>. If needed, follow same format ad for faculty. Do report disclosures for <em>any</em> activity that was peer reviewed.</strong></p>
</td>
</tr>

</table>
<h1>
<a name="Heading586"></a><strong>References</strong></h1>
<p>1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. <em>Arch Intern Med</em>. 2000;160:809-815.</p>

<p>2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. <em>JAMA</em>. 2005;293:715-722.</p>

<p>3. Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. <em>Eur J Cancer</em>. 2013;49:1404-1413.</p>

<p>4. Cronin-Fenton DP, S&oslash;ndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. <em>Br J Cancer</em>. 2010;103:947-953.</p>

<p>5. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. <em>Blood</em>. 2013;122:1712-1723.</p>

<p>6. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <em>Chest. </em>2012;141(2 suppl):e419S-e496S.</p>

<p>7. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <em>Chest</em>. 2016;149:315-352.</p>

<p>8. Lyman GH, Bohlke K, Falanga A, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <em>J Oncol Pract</em>. 2015;11:e442-e444.</p>

<p>9. Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <em>Res Pract Thromb Haemost</em>. 2017;1:14-22.</p>

<p>10. Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. <em>Oncologist</em>. 2013;18:1321-1329.</p>

<p>11. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. <em>N Engl J Med. </em>2018;378:615-624.</p>

<p>12. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <em>J. Clin Oncol</em>. 2018;36:2017-2023.</p>

<p>13. Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. <em>Thromb Haemost</em>. 2018. [Epub ahead of print].</p>

<p>14. van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <em>Thromb Haemost.</em> 2015;114:1268-1276.</p>

<p>15. Young A, Phillips J, Hancocks H, et al. OC-11 -- Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. <em>Thromb Res.</em> 2016;140:S172-S173.</p>

<p>16. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. <em>Thromb Haemost</em>. 2018;118:1439-1449.</p>

<p>17. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018. [Epub ahead of print].</p>

<p>18. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018;16:1246-1249.</p>

<p>19. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <em>J Thromb Thrombolysis</em>. 2016;41:81-91.</p>

<p>20. Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. <em>Thromb Haemost</em>. 2017;117:2135-2145.</p>

<p>21. Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <em>Thromb Res</em>. 2018;164:S124-S129.</p>


</body>

</html>
